
    
      Based on Good Post-marketing Study Practice (GPSP) regulation, general patient population
      with ischemic heart disease who are eligible for treatment with XIENCE PRIME SV Everolimus
      Eluting Stent will be registered, with no particular inclusion/exclusion criteria, and may be
      eligible for angiographic follow-up at eight months and clinical follow-up at one year.
    
  